



## SmartPA Criteria Proposal

Drug/Drug Class:	Cough and Cold Preparations PDL Edit		
First Implementation Date:	May 31, 2013		
Proposed Date:	April 18, 2023		
Prepared For:	MO HealthNet		
Prepared By:	MO HealthNet/Conduent		
Criteria Status:	□Existing Criteria ☑Revision of Existing Criteria □New Criteria		

## **Executive Summary**

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected:

The common cold is a viral illness that affects persons of all ages, prompting frequent use of over-the-counter and prescription medications, as well as alternative remedies. Cough and cold formulations are available for the use in the treatment of the signs and symptoms of the common cold, sinusitis, allergies, and cough. They come in various combinations as simple cold preparations, narcotic cough and cold formulations and non-narcotic cough and cold products. The MO HealthNet Pharmacy Program has identified the following products as FDA approved and available on the market. These listed agents will be the preferred products available first line, all other products are considered non-preferred.

Total program savings for the PDL classes will be regularly reviewed.

## Program-Specific Information:

	Preferred Agents		Non-Preferred Agents
	Benzonatate Caps	•	All Cough and Cold Preparations
	<ul> <li>Brompheniramine/Phenylephrine/</li> </ul>		not listed as preferred agents
	Dextromethorphan Soln		
	Brompheniramine/Psuedoephedrine		
	/Dextromethorphan Soln		
	<ul> <li>Carbinoxamine Tabs/Soln</li> </ul>		
	<ul> <li>Chlorpheniramine Tabs</li> </ul>		
	Chlorpheniramine/Phenylephrine Soln		
ľ	<ul> <li>Chlorpheniramine/Phenylephrine/</li> </ul>		
	Dextromethorphan Soln		
	<ul> <li>Cyproheptadine Soln/Tabs</li> </ul>		
	<ul> <li>Dextromethorphan Susp</li> </ul>		
	• Diphenhydramine		
	Guaifenesin Soln		
	Guaifenesin/Codeine Soln		
	Guaifenesin/Dextromethorphan Soln		
	Promethazine/Dextromethorphan Soln		

<sup>\*</sup>This is a representative list of products covered in the past and is not intended to be an all-inclusive list of reimbursable products. MO HealthNet will cover products based on a maximum dollar claim limit.

Type of Criteria:	<ul><li>☐ Increased risk of ADE</li><li>☐ Appropriate Indications</li></ul>	<ul><li>☑ Preferred Drug List</li><li>☐ Clinical Edit</li></ul>			
Data Sources:	☐ Only Administrative Databases	□ Databases + Prescriber-Supplied			
Setting & Population					
<ul> <li>Drug class for review: Cough and Cold Preparations</li> <li>Age range: All appropriate MO HealthNet participants</li> </ul>					
Approval Criteria					
Claim is for a preferred agent					
Denial Criteria					
<ul> <li>Prescription cost exceeds MO HealthNet established limit</li> <li>Therapy will be denied if all approval criteria are not met</li> </ul>					
Required Docum	nentation				
Laboratory Resul MedWatch Form					
Disposition of E	dit				
Denial: Exception Code "0213" (Prior Authorization Required But Not Found) Rule Type: PA					
Default Approva	l Period				
6 months					
References					

- Evidence-Based Medicine and Fiscal Analysis: "Cough and Cold Agents Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; January 2022.
- Evidence-Based Medicine Analysis: "Cough and Cold Remedies", UMKC-DIC; Last updated October 2022.
- USPDI, Micromedex; 2023.
- Facts and Comparisons eAnswers (online); 2023 Clinical Drug Information, LLC.